Document is current
Any future updates will be listed below
-
Authors
Guglielmi, Valeria
Musumeci, Giuseppe
Galeone, Carlotta https://orcid.org/0000-0003-1934-5167
Mariani, Paolo
Baratta, Roberto
Bellini, Rosario
Cameli, Matteo
Castaldini, Nicola
Cesaro, Arturo
Cosentino, Nicola
Della Riva, Diego
Di Gioia, Ludovico
Infante, Marco
Milone, Francesco
Mirani, Marco
Muscoli, Saverio
Ragozzino, Giovanni
Sani, Elena
Zenti, Maria Grazia
Pagotto, Uberto
Sbraccia, Paolo
-
Funding
Funding for this research was provided by:
Eli Lilly Italia (Not applicable)
- License Information
-
More Information
Article History
Received: 30 March 2026
Accepted: 30 July 2026
First Online: 12 August 2026
Declarations
Competing Interests: V.G.: Eli Lilly, Novo Nordisk. C.G.: Eli Lilly (participation in advisory board). N.Co.: Alnalym, Astra Zeneca, Aurora Biopharma, Bayer, Boehringer Ingelheim, Eli Lilly, Pfizer. L.D.G.: Eli Lilly, Roche Diabetes Care, MOVI SpA, Sanofi, Theras (honoraria); Abbott, Eli Lilly, Novo Nordisk, Sanofi (support for attending meetings or travels); Eli Lilly, Sanofi (participation on Advisory Boards). M.M.: Lilly Italia, Novo Nordisk, Astra Zeneca (travel grant and honoraria). S.M.: Eli Lilly, Novo Nordisk, Regeneron. G.R.: Eli Lilly, Bruno Farmaceutici, Astra Zeneca. U.P.: Advisory Board: Novo Nordisk, Boehringer Ingelheim, Lilly Italia; Speaker fee: Novo Nordisk, Astra Zeneca, Bruno Farmaceutici, Rhythm Pharma, International Medical Press, Lilly Italia, Merck; Unrestricted grant: Novo Nordisk; Editor in Chief of the Journal of Endocrinological Investigation. P.S.: serves/ed on scientific advisory boards and received honoraria or consulting fees from Boehringer Ingelheim, Chiesi, Eli Lilly, Novo Nordisk, Roche and Theras. Other authors have no competing interests to declare that are relevant to the content of this article.
